Advertisement

Topics

Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union

08:00 EDT 23 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to extend the current therapeutic i...

Other Sources for this Article

Alexion Pharmaceuticals, Inc.
Media
Arne Naeveke, PhD, 475-230-3774
Executive Director, Product Communications
or
Investors
Elena Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
or
Catherine Hu, 475-230-3599
Director, Investor Relations

NEXT ARTICLE

More From BioPortfolio on "Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...